Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
Black and Latino cancer patients have higher rates of coronavirus infection and hospitalization but are less likely to use telehealth.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
The panel’s goal is to ensure that all coronavirus therapeutics approved by the government are safe and effective for African Americans.
Some scientists are investigating how the virus enters humans cells, developing more efficient testing and searching for treatments.
However, experts caution that data from randomized clinical trials are still lacking.
Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.